Logo
Logo

About Relugolix API

Product
  • Therapeutic Category抗癌 / 肿瘤学

  • CAS Number

    737789-87-6

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Tablets, Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Brazil DMF

Mechanism of Action

Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.

Indication

ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.

Related APIs

恩扎卢胺

抗癌 / 肿瘤学

arrow

Adagrasib

抗癌 / 肿瘤学

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.